High-Content Imaging-Based Assay for SARS-CoV-2-Neutralizing Antibodies.

High-Content Imaging-Based Assay for SARS-CoV-2-Neutralizing Antibodies.

Publication date: Feb 24, 2024

The COVID-19 pandemic and the consequent emergence of new SARS-CoV-2 variants of concern necessitates the determination of populational serum potency against the virus. Here, we standardized and validated an imaging-based method to quantify neutralizing antibodies against lentiviral particles expressing the spike glycoprotein (pseudovirus). This method was found to efficiently quantify viral titers based on ZsGreen-positive cells and detect changes in human serum neutralization capacity induced by vaccination with up to two doses of CoronaVac, Comirnaty, or Covishield vaccines. The imaging-based protocol was also used to quantify serum potency against pseudoviruses expressing spikes from Delta, Omicron BA. 1.1. 529, and BA. 4/5. Our results revealed increases in serum potency after one and two doses of the vaccines evaluated and demonstrated that Delta and Omicron variants escape from antibody neutralization. The method presented herein represents a valuable tool for the screening of antibodies and small molecules capable of blocking viral entry and could be used to evaluate humoral immunity developed by different populations and for vaccine development.

Open Access PDF

Concepts Keywords
Covid antibodies
Pandemic high-content screening
Vaccines neutralization
Valuable SARS-CoV-2
variants

Semantics

Type Source Name
disease IDO assay
disease MESH COVID-19 pandemic
disease VO Glycoprotein
disease VO vaccination
disease VO CoronaVac
disease VO Comirnaty
disease VO protocol
disease VO vaccine
disease VO manufacturing
drug DRUGBANK Coenzyme M
disease MESH emergency
disease IDO country
disease VO effective
disease MESH severe acute respiratory syndrome
disease VO time
disease IDO virulence
disease VO organization
disease VO population
drug DRUGBANK Gold
disease MESH Infection
disease IDO algorithm
disease IDO production
disease MESH viral infection
disease VO USA
disease VO dose
drug DRUGBANK Phosphate ion
drug DRUGBANK Benzylpenicillin
drug DRUGBANK Streptomycin
drug DRUGBANK Angiotensin II
disease VO volume
disease IDO object
disease VO immunization
disease VO ANOVA
disease VO viable
disease IDO host
disease VO titer
drug DRUGBANK Cysteamine
disease VO vaccinated
disease VO immunized
disease IDO blood
drug DRUGBANK Aspartame
disease VO Viruses
disease VO gene
disease MESH point mutations
disease VO vaccine efficacy
disease VO antibody titer
disease VO unvaccinated
drug DRUGBANK Nonoxynol-9
drug DRUGBANK (S)-Des-Me-Ampa
disease IDO cell
drug DRUGBANK Guanosine
disease IDO infectivity

Original Article

(Visited 1 times, 1 visits today)